| | Appendix

Q2 2025 Financial Results



Alnylam Pharmaceuticals, Inc.

Reconciliation of Selected GAAP Measures to Non-GAAP Measures (In thousands)

	Three Months Ended				
		June 30, 2025		June 30, 2024	
Reconciliation of GAAP to Non-GAAP Research and development expenses:					
GAAP Research and development expenses	\$	323,621	\$	294,142	
Less: Stock-based compensation expenses		(49,552)		(48,115)	
Non-GAAP Research and development expenses	\$	274,069	\$	246,027	
Reconciliation of GAAP to Non-GAAP Selling, general and administrative expenses:					
GAAP Selling, general and administrative expenses	\$	323,314	\$	248,397	
Less: Stock-based compensation expenses		(62,128)		(41,173)	
Non-GAAP Selling, general and administrative expenses	\$	261,186	\$	207,224	
Reconciliation of GAAP to Non-GAAP Income (loss) from operations:					
GAAP (Loss) income from operations	\$	(16,199)	\$	48,614	
Add: Stock-based compensation expenses		111,680		89,288	
Non-GAAP Operating income	\$	95,481	\$	137,902	
Reconciliation of GAAP to Non-GAAP Net income (loss):					
GAAP Net loss	\$	(66,277)	\$	(16,889)	
Add: Stock-based compensation expenses		111,680		89,288	
Add: Realized and unrealized loss on marketable equity securities		1,350		1,367	
Less: Income tax effect of GAAP to non-GAAP reconciling items		(2,631)		_	
Non-GAAP Net income	\$	44,122	\$	73,766	



Alnylam Pharmaceuticals, Inc.

Reconciliation of Product Revenue and Growth at Constant Currency

	June 30, 2025
	Three Months Ended
Total TTR net product revenue growth, as reported	77 %
Add: Impact of foreign currency translation	(2)
Total TTR net product revenue growth at constant currency	75 %
Total Rare net product revenue growth, as reported	24 %
Add: Impact of foreign currency translation	(1)
Total Rare net product revenue growth at constant currency	23 %
Total net product revenue growth, as reported	64 %
Add: Impact of foreign currency translation	(2)
Total net product revenue growth at constant currency	62 %
Total revenue growth, as reported	17 %
Add: Impact of foreign currency translation	(1)
Total revenue growth at constant currency	16 %

